ProCE Banner Activity

Optimal Selection of New Molecules as Frontline Treatment of Chronic Lymphocytic Leukemia

Slideset Download
Download these slides from our ASH 2019 live satellite symposium on CLL to review the most current clinical data on treating patients with newly diagnosed CLL.

Released: December 05, 2019

Expiration: December 03, 2020

No longer available for credit.

Share

Faculty

Anthony Mato

Anthony Mato, MD, MSCE

Associate Professor
Division of Leukemia
Memorial Sloan Kettering Cancer Center
New York, New York

Provided by

Provided by National Comprehensive Cancer Network.
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

BeiGene Ltd

Janssen Biotech Pharmacyclics

Pharmacyclics an AbbVie Company

Faculty Disclosure

Primary Author

Anthony Mato, MD, MSCE

Associate Professor
Division of Leukemia
Memorial Sloan Kettering Cancer Center
New York, New York

Anthony Mato, MD, MSCE, has disclosed that he has received consulting fees from AstraZeneca, Celgene, Janssen, Loxo, Pfizer, Pharmacyclics, Sunesis, and TG Therapeutics and funds for research support from AstraZeneca, Celgene, DTRM, Janssen, Loxo, Pharmacyclics, Regeneron, Sunesis, and TG Therapeutics.